Data Insights

Satralizumab by F. Hoffmann-La Roche for Autoimmune Encephalitis (Post-Infectious): Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Autoimmune Encephalitis (Post-Infectious). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Autoimmune Encephalitis (Post-Infectious)

Data Insights

Satralizumab by F. Hoffmann-La Roche for Graves' Ophthalmopathy: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Graves' Ophthalmopathy. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Graves' Ophthalmopathy

Data Insights

Satralizumab by F. Hoffmann-La Roche for Demyelinating Diseases: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Demyelinating Diseases. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Demyelinating Diseases

Data Insights

Satralizumab by F. Hoffmann-La Roche for Duchenne Muscular Dystrophy: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Duchenne Muscular Dystrophy. According to...

Data Insights

Satralizumab by F. Hoffmann-La Roche for Demyelinating Diseases: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Demyelinating Diseases. According to GlobalData,...

Data Insights

Satralizumab by F. Hoffmann-La Roche for Myasthenia Gravis: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Myasthenia Gravis. According to GlobalData,...